Susquehanna International Group, LLP Milestone Pharmaceuticals Inc. Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$1.43 - $2.36 $66,924 - $110,448	46,800 New	46,800 $110,000
Q2 2024 Aug 15, 2024	BUY	$1.29 - $1.83 $21,801 - $30,927	16,900 New	16,900 $22,000
Q1 2023 May 16, 2023	SELL	$3.14 - $4.2 $237,070 - $317,100	-75,500 Reduced 85.12%	13,200 $52,000
Q4 2022 Feb 14, 2023	BUY	$3.53 - $9.5 $61,069 - $164,350	17,300 Added 24.23%	88,700 $351,000
Q3 2022 Nov 14, 2022	BUY	$5.86 - $9.43 $418,404 - $673,302	71,400 New	71,400 $656,000
Q1 2022 May 16, 2022	BUY	$4.1 - $8.24 $45,509 - $91,464	11,100 New	11,100 $71,000
Q4 2021 Feb 14, 2022	SELL	$5.47 - $7.13 $189,262 - $246,698	-34,600 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.28 - $6.29 $372,768 - $444,074	-70,600 Reduced 67.11%	34,600 $198,000
Q2 2021 Aug 11, 2021	BUY	$5.22 - $6.11 $134,154 - $157,027	25,700 Added 32.33%	105,200 $579,000
Q1 2021 May 17, 2021	BUY	$5.79 - $8.85 $460,305 - $703,575	79,500 New	79,500 $460,000

25.1M

61.2K

38.8K

Ticker MIST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,010,900
Market Cap $48.9M
Description
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.